Loading...
Eighty percent of patients with cystic fibrosis (CF) become colonized with Pseudomonas aeruginosa. Systemic aminoglycosides are the standard treatment, but administration by inhalation could deliver high antibiotic concentrations directly to infected endobronchial tissue with minimal systemic exposure and toxicity. A preservative-free formulation of tobramycin for inhalation, developed to avoid bronchoconstriction and side effects from additives, has been shown safe and effective in phase III studies (Journal Watch Infectious Diseases Apr 1999). This manufacturer-sponsored report details bioavailability data from those studies.
Patients with CF and P. aeruginosa infections inhaled tobramycin (300 mg) twice daily for 28 days, followed by 28 d…